Capricor Therapeutics to Host Investor Webcast
Capricor Therapeutics, Inc. CAPR is gearing up to share significant updates on its Duchenne muscular dystrophy (DMD) program during an upcoming investor webcast. This event is scheduled for 8:30 a.m. ET on a Tuesday. The aim of the webcast is to convey important regulatory news, which stems from recent discussions between the company and the U.S. Food and Drug Administration (FDA).
Details for the Exciting Webcast
During the webcast, attendees will have the chance to learn more about the latest developments in DMD research being spearheaded by Capricor. If you'd like to participate in the conference call, you can reach out using 1-800-717-1738 for domestic callers or 1-646-307-1865 for those calling from abroad. An operator will be there to assist you.
Joining the Webcast
If you prefer a digital option, you can also join the live event through a user-friendly online interface. Those who want to attend via the webcast can easily follow a special link that will direct them to the presentation materials and slides. After the live session wraps up, a replay will be made available on Capricor’s website for those who couldn't catch it live.
Getting to Know Capricor Therapeutics
Capricor Therapeutics is a forward-thinking biotechnology company focused on creating innovative cell and exosome-based therapies that target rare diseases. Their lead product, deramiocel (CAP-1002), is an allogeneic cardiac-derived cell therapy that has shown encouraging results in both preclinical studies and clinical trials, especially concerning dystrophinopathies and heart-related issues. Currently, deramiocel is advancing through Phase 3 clinical trials aimed at treating Duchenne muscular dystrophy.
Advancements in Exosome Technology
Alongside deramiocel, Capricor is also pushing forward with its exosome technology using its proprietary StealthX™ platform. This innovative method seeks to enhance the precise delivery of therapies, which could significantly change treatment options for a range of diseases, including those related to vaccines and oligonucleotide delivery.
Ongoing Commitment to Transformative Therapies
Capricor is deeply dedicated to research and the progression of medical treatments. The firm continuously examines new possibilities to enhance health outcomes for patients with rare diseases. They take pride in challenging the limits of scientific innovation, aiming to provide their groundbreaking therapies to those in need.
Looking Forward: Future Aspirations
The continuing partnership between Capricor and its strategic allies reflects the company's commitment to collaborating on advanced research and development in the biotech field. As Capricor navigates the complexities of regulatory requirements, their unwavering focus is on delivering transformative treatments that can significantly improve the quality of life for patients with rare diseases.
Frequently Asked Questions
What is the purpose of the upcoming investor webcast?
The webcast is intended to share updates on Capricor’s Duchenne muscular dystrophy program, specifically regarding regulatory developments with the FDA.
When is the investor webcast scheduled?
The investor webcast will take place at 8:30 a.m. ET on a Tuesday, with further details provided on how to participate.
What is deramiocel and why is it significant?
Deramiocel (CAP-1002) is a groundbreaking cell therapy that is currently in Phase 3 trials for treating Duchenne muscular dystrophy, showing promising results across various clinical applications.
How does Capricor make use of exosome technology?
Capricor employs exosome technology through its StealthX™ platform, with the goal of enhancing targeted delivery of therapeutics for a broad spectrum of diseases.
Who can I contact if I need more information?
For additional inquiries, you can contact Capricor’s media representative, Raquel Cona, at KCSA Strategic Communications at 212.896.1204.
